

CURRICULUM VITAE

Education

| | | |
|------|--|--|
| 1998 | Fellowship | American College of Endocrinology |
| 1995 | Certification, Endocrinology & Metabolism | Royal College of Physicians Canada, American Board of Internal Medicine |
| 1994 | Fellowship, Internal Medicine | Royal College of Physicians Canada, American Board of Internal Medicine |
| 1990 | Doctor of Medicine | University of Toronto |

Professional Activities

| | | |
|----------------------|-----------------------|--------------------------------------|
| Oct 2015- Present | Chief Medical Officer | LMC Diabetes & Endocrinology |
| 1997-2015 | Executive Director | LMC Diabetes & Endocrinology |
| 1995-2001 | Staff Endocrinologist | Oakville Trafalgar Memorial Hospital |

Key Publications

Exercise & Diabetes

- **Aronson R, Brown R, Li A, Riddell M. Optimal insulin correction factor in post-high-intensity exercise hyperglycemia in adults with type 1 diabetes: The FIT Study. Diabetes Care 2019;42(1): 10-16.**
- Riddell M, Pooni R, Yavelberg L, Li Z, Kollman C, Brown R, Li A, Aronson R. Reproducibility in the cardiometabolic responses to high-intensity interval exercise in adults with type 1 diabetes. Diab Res Clin Prac 2019;148:137-143.
- Li A, Riddell M, Potashner D, Brown R, Aronson R. Time Lag and Accuracy of Continuous Glucose Monitoring During High Intensity Interval Training in Adults with Type 1 Diabetes. Diabetes Technol Ther 2019;21(5).

Skills Confidence Preparedness Index (SCPI)

- **Aronson R, Brown RE, et al. Assessment of self-management in patients with diabetes using the novel LMC Skills, Confidence and Preparedness Index (SCPI). Diabetes Res Clin Prac 2018;137:128-136.**
- Mbuagbaw L, Aronson R, et al. The LMC Skills, Confidence & Preparedness Index (SCPI): development and evaluation of a novel tool for assessing self-management in patients with diabetes. Health Qual Life Outcomes 2017;15(1):27.

Epidemiology Insights from the LMC Diabetes Registry

- **Aronson R, Orzech N, Ye C, Brown R, Goldenberg R, Brown V. Specialist-led Diabetes Registries and Prevalence of Poor Glycemic Control in Type 2 Diabetes: The Diabetes Registry Outcomes Project for A1c Reduction (DROP A1C). Diabetes Care 2016;39(10):1711-7.**
- **Aronson R, Orzech N, Ye C, Goldenberg R, Brown V. Specialist-led Diabetes Registries and Predictors of Poor Glycemic Control in Type 2 Diabetes: Insights into the Functionally Refractory Patient from the LMC Diabetes Registry Database. J Diabetes 2016;8(1):76-85.**
- Bajaj H, Venn K, Ye C, Patrick A, Kalra S, Khandwala H, Aslam N, Twum-Barima D, Aronson R. Lowest Glucose Variability and Hypoglycemia Are Observed With the Combination of a GLP-1 Receptor Agonist and Basal Insulin (VARIATION Study). Diabetes Care 2017 Feb;40(2):194-200.
- Bajaj H, Venn K, Ye C, Aronson R. Randomized Trial of Long-Acting Insulin Glargine Titration Web Tool (LTHome) Versus Enhanced Usual Therapy of Glargine Titration (INNOVATE Trial). Diabetes Technology & Therapeutics 2016;18(10):610-615.
- Bajaj H, Ye C, Jain E, Venn K, Stein E, Aronson R. Glycemic Improvement with a Fixed-dose combination of DPP-4 inhibitor + metformin in patients with Type 2 diabetes (GIFT study). Diab Obes Metab 2017;20(1):195-199.
- Bajaj H, Brown R, Bhullar L, Sohi N, Kalra S, Aronson R. SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes. Diabet Metab 2018;44(6):493-499.
- Brown R, Gupta N, Aronson R. Effect of dapagliflozin on glycemic control, weight, and blood pressure in patients with type 2 diabetes attending a specialist endocrinology practice in Canada: a retrospective cohort analysis. Diabetes Technology & Therapeutics 2017;19(11):685-691.

Technology in Diabetes

- **Aronson R, Reznik Y, Conget I., et al. Sustained efficacy of insulin pump therapy, compared with multiple daily injections, in type 2 diabetes (OpT2mise study). Diab Obes Metab 2016;18(5):500-7.**
- **Aronson R, Cohen O, Conget I et al. OpT2mise: a randomized controlled trial to compare insulin pump therapy with multiple daily injections in the treatment of type 2 diabetes-research design and methods. Diabetes Technology & Therapeutics 2014 Jul;16(7):414-20.**
- Reznik Y, Cohen O, Aronson R. Insulin pump treatment compared with MDI for treatment of type 2 diabetes (Op2mise): a randomised open-label controlled trial. Lancet 2014;384(9950):1265-72.
- Metzger M, Castaneda J, Aronson R, et al. Factors associated with improved glycemic control following continuous subcutaneous insulin infusion therapy in patients with type 2 diabetes uncontrolled with bolus-basal insulin regimens: an analysis from the OpT2mise randomized trial. Diabetes Obes Metab 2017;19(10): 1490-1494.

Hypoglycemia in Diabetes

- **Aronson R, Goldenberg R, et al. The Canadian Hypoglycemia Assessment Tool Program. Can J Diabetes 2017;42(1):11-17.**
- Aronson R, Galstyan G, Goldfracht M, et al. Direct and indirect health economic impact of hypoglycaemia in a global population of patients with insulin-treated diabetes. Diab Res Clin Prac 2018;138:35-43.
- Pedersen-Bjergaard, U et al. Comparison of the HAT study, the largest global hypoglycaemia study to date, with similar large real-world studies. Diab Ob Metab 2018;21(4):844-853.
- Khunti K, Alsifri S, Aronson R, et al. Impact of hypoglycaemia on patient-reported outcomes from a global, 24-country study of 27,585 people with type 1 and insulin-treated type 2 diabetes. Diabetes Res Clin Pract 2017;130:121-9. doi: 10.1016/j.diabres.2017.05.004

- Khunti K, Alsifri S, Aronson R, et al. Rates and predictors of hypoglycaemia in 27,585 people from 24 countries with insulin-treated type 1 and type 2 diabetes: the global HAT study. *Diabetes Obes Metab* 2016;18:907-15.

Collaborative Research

- Aronson R, Frias J, Goldman A, et al. Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study. *Diab Ob Metab* 2018;20(6):1453-1460.
- Aronson R, Umpierrez G, Stager W, Kovatchev B. Insulin glargine/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia. *Diab Obes Metab* 2018;21(3):726-731.
- Beck RB, Riddlesworth TD, Aronson R, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes. *Ann Intern Med* 2017;167(6):365-374.
- Rosenstock J, Aronson R, et al. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled With Oral Agents: The LixiLan-O Randomized Trial. *Diabetes Care* 2016;39(11):2026-35.
- Bajaj H, Aronson R, et al. The Need Associated with Diabetes Primary Care and the Impact of Referral (NADIR Study). *Can J Diabetes* 2016;40(2):120-125.
- Rosenstock J, Guerci B, Hanefeld M, Gentile S, Aronson R, et al. Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial. *Diabetes Care* 2016 Aug;39(8):1318-28.
- Hanefeld M, Berria R, Lin J, Aronson R et al. Lixisenatide treatment for older patients with type 2 diabetes mellitus uncontrolled on oral antidiabetics: meta-analysis of five randomized controlled trials. *Advanced Therapeutics* 2014;31(8):861-872.
- Ahren B, Gaultier JF, Berria R, Stager W, Aronson R, Bailey CJ. Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials. *Diabetes Obes Metab* 2014;16(9):861-868.
- Sacks FM, Hermans MP, Fioretto P, Valensi P, Davis T, Horton E, Wanner C, Al-Rubeaan K, Aronson R, et al. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. *Circulation* 2014;129(9):999-1008.
- Pinget M, Goldenberg R, et al, Aronson R. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P). *Diabetes Obes Metab* 2013;15(11):1000-7.
- Riddle MC, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin (GetGoal-L). *Diabetes Care* 2013;36(9):2489-2496.
- Riddle M, Souhami E, Forst T, Silvestre L, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). *Diabetes Care* 2013; 36(9):2497-503.

Reviews

- Aronson R. Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin. *Curr Med Res Opin* 2015;31(5):901-11.
- Aronson R. The Functionally Refractory Patient in Diabetes – Prevalence and Predictors within Specialist Care Registries. *US Endocrinology* 2015;11(1):30-1.

- Aronson R, Gibney MA, et al. Insulin pen needles: effects of extra-thin wall needle technology on preference, confidence, and other patient ratings. *Clin Ther* 2013;35(7):923-933.
- Aronson R. Optimizing glycemic control: lixisenatide and basal insulin in combination therapy for the treatment of type 2 diabetes. *Expert Rev Clin Pharmacol* 2013;6(6):603-612
- Aronson R. The role of comfort and discomfort in insulin therapy. *Diabetes Technology & Therapeutics* 2012;14(8):741-7.